将 Pembrolizumab 转化为临床实践：讲免疫学，快速学习！
Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!
机构信息
BioNovion B.V., Oss, the Netherlands.
Division of Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
出版信息
Clin Cancer Res. 2015 Oct 1;21(19):4251-3. doi: 10.1158/1078-0432.CCR-15-1126. Epub 2015 Jul 13.
Abstract
T-cell checkpoint inhibitors treat the cancer patient's immune system potentially inducing significant long-term survival. Pembrolizumab demonstrates clinical activity in patients diagnosed with melanoma and other cancers. Its mode of action suggests a rationale for combination with other treatment modalities, urging oncologists to brush up their knowledge of immunology.
摘要
T 细胞检查点抑制剂可以治疗癌症患者的免疫系统，从而有可能带来显著的长期生存。派姆单抗在诊断为黑色素瘤和其他癌症的患者中显示出临床活性。其作用机制提示了与其他治疗方式联合应用的合理性，促使肿瘤学家更新其免疫学知识。
相似文献
1
Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!
Clin Cancer Res. 2015 Oct 1;21(19):4251-3. doi: 10.1158/1078-0432.CCR-15-1126. Epub 2015 Jul 13.
2
LIGHT May Improve Immune Checkpoint Blockade Response.
Cancer Discov. 2016 Jun;6(6):OF9. doi: 10.1158/2159-8290.CD-NB2016-042. Epub 2016 Apr 14.
3
A Translational Perspective of a Deubiquitinase Inhibitor in Antitumor Immunity.
EBioMedicine. 2016 Nov;13:7-8. doi: 10.1016/j.ebiom.2016.11.008. Epub 2016 Nov 8.
4
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.
5
Immune Checkpoint Therapy in Melanoma.
Cancer J. 2016 Mar-Apr;22(2):73-80. doi: 10.1097/PPO.0000000000000183.
6
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.
Clin Cancer Res. 2016 Apr 15;22(8):1865-74. doi: 10.1158/1078-0432.CCR-15-1507.
7
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.
Clin Cancer Res. 2015 Oct 1;21(19):4327-36. doi: 10.1158/1078-0432.CCR-15-0357.
8
Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
Cancer J. 2016 Mar-Apr;22(2):68-72. doi: 10.1097/PPO.0000000000000185.
9
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Curr Opin Immunol. 2015 Apr;33:23-35. doi: 10.1016/j.coi.2015.01.006. Epub 2015 Jan 23.
10
Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Expert Rev Anticancer Ther. 2015;15(9):981-93. doi: 10.1586/14737140.2015.1074862. Epub 2015 Jul 30.
Zotero 插件